Short-Term High-Flow Nasal Cannula for Moderate to Severe Bronchiolitis Is Effective in a General Pediatric Ward

Area of Science:

• Pediatrics
• Respiratory Medicine
• Medical Devices

Background:

• Bronchiolitis is a common respiratory infection in infants and young children.
• Current treatments may not always be sufficient for moderate to severe cases.
• Heated humidified high-flow nasal cannula (HHHFNC) is an emerging therapy for respiratory distress.

Purpose of the Study:

• To evaluate the clinical and physiological benefits of HHHFNC in pediatric bronchiolitis.
• To assess the safety and efficacy of HHHFNC in a general pediatric ward setting.

Main Methods:

• A study involving 16 children aged 0-2 years with moderate to severe bronchiolitis.
• Patients were treated with HHHFNC and evaluated using the Wang et al Bronchiolitis Severity score and transcutaneous CO2 monitoring.
• Assessments were conducted at 4- to 10-hour intervals, both on and off the device.

Main Results:

• Significant improvement in the Bronchiolitis Severity score by 3 points (P = .001).
• Average reduction of 8.7 mm Hg in transcutaneous CO2 levels (P = .001).
• No adverse effects were reported during HHHFNC use.

Conclusions:

• HHHFNC is a safe and effective treatment for moderate to severe pediatric bronchiolitis in a general ward.
• The therapy led to immediate clinical and physiological improvements.
• Benefits were sustained for 1 to 4 hours after device disconnection.